Medicine for bird influenza treatment

FIELD: medicine; veterinary.

SUBSTANCE: medicine for bird influenza treatment includes activated-potentiated form of antibodies to bird alpha, beta and gamma interferon obtained by multiple sequential cultivation and external affection by homeopathic technology.

EFFECT: improved efficiency of treatment.

4 cl, 3 ex

 

The invention relates to medicine, namely to veterinary medicine, and can be used for effective treatment and prevention of influenza in poultry, mainly chickens.

In the prior art it is known that as medicines for the treatment and prophylaxis of viral infections in domestic animals used polyvalent serum containing antibodies to pathogens relevant diseases (Liping A. Sanin A., Zinchenko E.V. VETERINARY HANDBOOK. Traditional and non-traditional methods of treatment of dogs. M., 2002, s-480). However, specific drugs for the effective treatment and prevention of influenza in birds almost none.

The invention is directed to create drugs based on antibodies for effective treatment and prevention of influenza in poultry, mainly chickens.

The solution of this problem is provided by the fact that the drug is for treatment of influenza in birds contains activated - potentiated form of antibodies to interferon alpha, beta or gamma birds, obtained by repeated consecutive dilution and external influences on homeopathic technology, contributing to their ultra-low dose.

This medicinal product may contain a combination of activated - potentiated forms of antibodies according to cnym interferon birds alpha, beta or gamma, or the activated - potentiated form of a mixture of different antibodies to interferon birds of alpha, beta or gamma.

In addition, the drug contains a mixture of homeopathic dilutions of antibodies to interferon alpha, beta or gamma birds in the activated - potentiated form.

Obtained in accordance with the invention, the drug represents a new pharmacological agent on the basis of antibodies, which is characterized by the presence of specific pharmacological activity, high efficiency and almost no side effects, which is confirmed experimentally. In addition, declared the drug has a environmentally friendly and low cost.

The drug is prepared as follows.

To generate antibodies to interferon alpha, beta or gamma birds used as immunogen for immunization of laboratory animals (rabbits). The obtained antibodies purified by the method of affinity chromatography. As immunogen can also be used a mixture of different fragments.

Method for producing polyclonal immune and monoclonal antibodies are described, for example, in the book: Immunological methods / edited Grimes, M.: Medicine, 1987. p.9-33. Method for producing natural antibodies is described, for example, in the book. Natural antibodies to low molecular weight compounds. Magagawa. M: at MSFU, 2001 (ISBN 5-8135-0058-8), p.70-114. Method for producing recombinant antibodies are described, for example, article Laffly, E., R. Sodoyer Hum. Antibodies. Monoclonal and recombinant antibodies, 30 years after. - 2005 - Vol.14. - N 1-2. P.33-55.

The selected antibodies are sequentially repeatedly diluted and subjected to external impact, predominantly vertical shaking, to obtain an activated form of ultra-low doses, for example, by homeopathic technology potentiation (see, for example. Usabe, Homeopathic medicines. A guide to description and manufacturer. Moscow, 1967, p.12-38). This produces a uniform decrease in the concentration by serial dilution of 1 volume part of the original substance (antibody) 9 volume parts (for decimal dilution (D) or 99 volumetric parts (for centesimal dilution (C) neutral solvent with multiple vertical shaking each received cultivation and use mostly separate containers for each subsequent dilution to obtain the required dose dilution (potency).

External processing in the process of reducing the concentration can be realized by ultrasound, electromagnetic or other physical effects.

Thus prepared Leka is the only tool used mainly in taken in homeopathic practice, pharmaceutical forms and dilutions in the form of alcoholic or aqueous solutions or tablets (pellets), obtained by soaking before saturation is contained in the dosage form neutral filler obtained potentiated solution - activated form of antibodies.

To improve therapeutic effect of the medicinal product may contain a mixture of different homeopathic dilution of antibodies in the activated - potentiated form.

Example 1.

Laying hens breed Livorno mass 980-1030 g experimental groups of 20 chickens, infected respiratory virus lethal dose (3 LD50) avian influenza H5N1 (avian flu), gave freely available aqueous solution of ultra-low doses of antibodies in the activated - potentiated form to interferon gamma chickens - a mixture of homeopathic dilution C12+C30+C200 (ULD anti-IFN-gamma) for 2 days before infection and 7 days after infection (in the control group of 20 chickens infected chickens received distilled water in the same mode).

In the result of infection with a lethal dose of the virus in chickens in both groups quickly died, with clinical signs of disease have not had time to develop. Of the 20 chickens from the experimental group survived 11 chickens in the control group survived only 5 chickens (the share of the surviving chickens in the experimental group 2.2 times (p<0,05) more share of the surviving chickens in the control group). On the 4th day after infection, the concentration of AIV in the lung tissues in chickens con the roll group was on average 12% higher than females experienced group receiving the drug in the form of an activated - potentiated form of antibodies to interferon gamma chicken (ULD anti-IFN-gamma).

Thus, the drug in the form of an activated - potentiated form of antibodies to interferon gamma chicken (ULD anti-IFN-gamma) upon infection with a lethal dose of influenza virus in birds contributes to the inhibition of development of infectious process in the lungs and reduces the mortality of chickens infected with bird flu.

Example 2.

Laying hens breed Livorno mass 980-1030 g experimental groups of 20 chickens, infected respiratory virus lethal dose (3 LD50) virus avian influenza H5N1 (avian flu), gave freely available aqueous solution containing a mixture of polyclonal antibodies to gamma interferon birds in the activated - potentiated form (a mixture of homeopathic dilution C12, C30 and C200) and polyclonal antibodies to alpha interferon birds in the activated - potentiated form (homeopathic dilution D50) within 2 days before infection and 7 days after infection (in the control group of 20 chickens infected chickens received distilled water in the same mode).

Of the 20 chickens from the experimental group survived 18 chickens in the control group survived only 7 chickens (the share of the surviving chickens in the experimental group 2.6 times (p<0,05) more share survived the chickens in the control group). Clinical signs of disease in both groups was observed only for those chickens that died after exposure dose 3 LD50. However, chickens have been reported following the outward signs of the disease: 1) confusion, lethargy, 2) light, 3) poor coordination, 4) convulsions, 5) meningeal symptoms at the time of his death. The number of clinical signs of disease in chickens from the experimental group treated with the drug per 1 animal was 1.8 times less than in control. On the 4th day after infection, the concentration of AIV in the lung tissues in chickens of the control group was on average 15% higher than females experienced group receiving the drug.

Thus, the drug in a mixture of polyclonal antibodies to gamma interferon birds in the activated - potentiated form (a mixture of homeopathic dilution C12, C30 and C200) and polyclonal antibodies to alpha interferon birds in the activated - potentiated form (homeopathic dilution D50) infection of chickens with a lethal dose of influenza virus in birds has a therapeutic effect, which is manifested in its ability to increase the rate of survival of infected chickens and to inhibit the reproduction of virus in the tissue of the lungs of birds.

Example 3.

Laying hens breed Livorno mass 980-1030 g experimental groups of 20 chickens, infected respiratory virus is m a lethal dose (3 LD 50) virus avian influenza H5N2 strain (AIV), gave freely available aqueous solution of ultra-low doses in the activated - potentiated form of a mixture of antibodies to interferon alpha and interferon beta chickens in homeopathic dilution NWB (ULD anti-IFN) for 2 days before infection and 7 days after infection (in the control group of 20 chickens infected chickens received distilled water in the same mode).

Of the 20 chickens from the experimental group survived 19 chickens in the control group survived only 7 chickens. Clinical signs of disease in both groups was observed only for those chickens that died after exposure dose 3 LD50. However, chickens have been reported following the outward signs of the disease: 1) confusion, lethargy, 2) light, 3) poor coordination, 4) convulsions, 5) meningeal symptoms at the time of his death. The number of clinical signs of disease in chickens from the experimental group treated with ULD anti-IFN, per 1 animal was 1.9 times less than in control. On the 4th day after infection, the concentration of AIV in the lung tissues in chickens of the control group was on average 15% higher than females experienced group receiving ULD anti-IFN).

Thus, the drug in the form of an activated - potentiated form of a mixture of antibodies to interferon alpha and interferon beta chicken contamination to the R of the influenza birds has a therapeutic effect, expressed in its ability to increase the rate of survival of infected chickens (the share of the surviving chickens in the experimental group 2.7-fold (p<0,05) more share of the surviving chickens in the control group) and to inhibit the reproduction of virus in the tissue of the lungs of birds.

1. Drug for treatment of influenza in birds, characterized in that it contains an activated - potentiated form of antibodies to interferon alpha, beta or gamma birds, obtained by repeated consecutive dilution and external influences on homeopathic technology, leading ultra-low dose of the antibody.

2. The drug according to claim 1, characterized in that it contains a combination of activated - potentiated forms of antibodies to various interferons birds - alpha, beta or gamma.

3. The drug according to claim 1, characterized in that it contains an activated - potentiated form of a mixture of different antibodies to interferon birds of alpha, beta or gamma.

4. The drug according to claim 1, characterized in that it contains a mixture of different homeopathic dilution of antibodies to interferon alpha, beta or gamma birds in the activated - potentiated form.



 

Same patents:

FIELD: medicine; pediatrics.

SUBSTANCE: by the first vaccination of 3-18 months old children vaccination is performed at least over 60 days after their arrival to Far North regions from other climatic zones.

EFFECT: high vaccination efficiency due to taking in consideration processes of child organism adaptation to a change of climatic zones.

7 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention claims application of starches substituted by quarterly ammonium groups with substitution degree of 0.4 to 3.0 with the help of a linker, in infection diseases treatment. Suppression of 1 type herpes virus replication by the claimed starches is demonstrated, in comparison to zero antivirus effect of non-modified starches. Minimal inhibiting concentration for staphylococci and mycobacteria is 5-60 g/l.

EFFECT: efficient infection disease treatment by the claimed starches.

5 cl, 7 tbl

FIELD: chemistry, pharmaceuticals.

SUBSTANCE: invention pertains to compounds with formula (I), their pharmaceutical salts or N-oxide used as an inhibitor to replication and/or proliferation of HCV, to the method of inhibiting replication or proliferation of hepatitis C virion using formula (I) compounds, as well as to pharmaceutical compositions based on them. The compounds can be used for treating or preventing infections, caused by hepatitis C virus. In general formula (I) cycle B is an aromatic or non-aromatic ring, which contains two heteroatoms, where X and Y, each is independently chosen from C, CH, N or O, under the condition that, both X and Y are not O and that, both X and Y are not N; U and T represent C; Z represents -CH-; A represents N or -CR2-; B represents -CR3-; D represents N or -CR4-; E represents N or -CR5-; G represents N or -CR6-; J represents N or -CR14-; K represents -CR8-; L represents N or -CR9-; M represents N or -CR10-; R2 and R6, each is independently chosen from a group, consisting of hydrogen, halogen, C1-C6alkyl, substituted C1-C6alkyl, C1-C6alkoxy, C1-C6substituted alkoxy, C1-C6alkoxycarbonyl, cycloheteroalkyl, substituted cycloheteroalkyl, -O-carbamoil, substituted -O-carbamoil, halogen C1-C6alkyl, diC1-C6alkylamino, substituted diC1-C6alkylamino and sylye ethers, where cycloheteroalkyl is a 3-7-member ring, containing 1-2 heteroatoms, chosen from N and O, under the condition that, one of R2 and R6 is not hydrogen; R3 and R5, each is independently chosen from a group, consisting of hydrogen, halogen; R4 represents hydrogen; R7 represents - NR11C(O)R12; R8, R9, R10 and R14, each is independently represents hydrogen; R11 represents hydrogen, C1-C6alkyl; and R12 is chosen from a group, consisting of halogen C1-C6alkyl; where each substituted group is substituted with one or more groups, chosen from -Q, -R40, -OR40, -C(O)R40, -C(O)OR40, where each Q independently represents halogen, R40 and R41 are independently chosen from a group consisting of hydrogen, C1-C6alkyl, C1-C6alkoxy, under the condition that: (i) at least one of A, D, E, G, J, L or M represents N; (ii) not more than one of A, D, E or G represents N; and (iii) not more than one of J, L or M represents N.

EFFECT: obtaining pyridyl-substituted heterocycles for treating and preventing infections, caused by hepatitis C virus.

33 cl, 85 dwg, 101 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science. Medicinal agent applied for prevention and treatment of bird viral influenza is represented with polystibuim. Polystibium inhibits infectious activity of influenza virus.

EFFECT: development of effective method applied for treatment and prevention of bird influenza.

6 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medical products and concerns combination for HIV-infection treatment, containing (a) therapeutically effective amount of HIV-protease inhibitor by formula or its pharmaceutically accepted salt or ester and (b) effective amount of rhytonavir or its pharmaceutically accepted salt or ester. Besides, method of improved pharmacokinetics of HIV-protease inhibitor by formula (4) or its pharmaceutically accepted salt or ester, including introduction to an individual requiring such treatment, therapeutically effective amount of rhytonavir or its pharmaceutically accepted salt or ester with therapeutically effective amount of specified HIV-protease inhibitor by formula (4) is described.

EFFECT: offered combination has synergetic action if taken in any molar ratios.

33 cl, 6 dwg, 9 tbl, 4 ex

FIELD: bioengineering.

SUBSTANCE: novel polynucleotide is invented which is produced from the nucleotide sequence of the IFNα-17 gene, containing the single nucleotide polymorphism SNP g771c. Also, the novel polynucleotide is invented which is derived from the natural protein IFNα-17 of the wild type containing SNP G45R.

EFFECT: can be used for producing effective therapeutic agent with antiviral, antiproliferative and/or immunomodulating activity.

13 cl, 5 dwg, 6 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention refers to creation and application of aerosol spray compositions for treatment of diseases or disorders requiring lowering of cell proliferation and/or induction of cell apoptosis, such as neoplastic, autoimmune, viral diseases. Agent contains as active substance vitamin E based composition of structural formula , where R1 is carboxylic acid; R2 and R3 are hydrogen or R4; R4 is methyl, and R5 is alkyl; or where R1 is hydrogen or carboxylic acid; R2 and R3 are hydrogen or R4; R4 is methyl, and R5 is alkenyl.

EFFECT: improved delivery of specified composition by inhalation with intensified antiproliferation activity.

59 cl, 17 dwg, 6 tbl, 35 ex

FIELD: medicine.

SUBSTANCE: method of production of dry polyvalent virus-vaccine includes separate infection of cell culture with strain PC-126 of turkey herpesvirus (virus of Marek's disease 3rd serotype) and one-day chicken infected with chicken herpesvirus (virus of Marek's disease 2nd serotype), incubation, turkey herpesvirus harvest, and sampling of double flag follicles of chicken herpesvirus infected chicken, protective medium addition, separate ultrasonic processing of virus cell mass and flag follicle mass, freezing and drying of end product followed with their mixing. At that chicken herpesvirus strain are sampled for (VMD 2nd serotype) strains "42", "50", "SB-1", inoculated in dosage 10000-50000 functional residual capacity (FRC) for chicken and grown in body within 12-25 days. Follicles processed with ultrasonic is removes, and protective medium processed with ultrasonic and containing released chicken herpesvirus is added equal proportion of processed with ultrasonic clean cell cultures of bird embryos grown within 24-72 hours. Dry polyvalent virus-vaccine contains cell-free lyophilized strain FC-126 of turkey herpesvirus - 3rd serotype of Marek's disease virus in protective medium. In addition virus-vaccine includes cell-free lyophilised strains of chicken herpesvirus - 2nd serotype of Marek's disease virus, produced by any cl.1-5, in protective medium at ratio 2000 FRC /units: 100-5 00 FRC /units, respectively.

EFFECT: vaccine has high immunogenic activity and storage stability.

10 cl, 3 tbl, 4 ex

Poplar-aspen oil // 2326685

FIELD: medicine; pharmacology.

SUBSTANCE: agent contains oil extract of poplar buds and sprouts and oil extract of aspen buds and sprouts with component ratio as follows, mass.%: oil extract of poplar buds and sprouts 20-90, oil extract of aspen buds and sprouts 10-80, mixed oil extract of poplar buds and sprouts and oil extract of aspen buds and sprouts, with component ratio as follows, mass.%: oil extract of poplar buds and sprouts 20-90, oil extract of aspen buds and sprouts 10-80, as well as fat extract of plant raw with plant component ratio as follows, mass.: marsh tea 3, comfrey 3, blueash 2, silver fir 1, common burdock (root) 2, horseheal (root) 1, deer's-tongue 1, horseradish 1, musquash-poison 2, hog bean (herb) 2, hop (cones) 2, cowberry (root) 2, mountain arnica (blossom) 2, ratio of oil extracts and fat extract of plant raw is 1:3 respectively.

EFFECT: agent allows widening range of preventive and therapeutic herbal medicinal agents of antiviral and anti-inflammatory action.

2 cl, 9 ex

FIELD: veterinary; veterinarian virology.

SUBSTANCE: production of dry cultural rinderpest virus-vaccine for minor ruminants includes growing of virus containing raw materials from "45G37/35-K" rinderpest virus strain in cell culture, introduction of protective medium and production of the end product. Passaged cell culture of saiga kidney is used as a cell culture. Infected culture is incubated under roller conditions during 5-7 days with the change of supporting medium each 2-3 days. Virus containing culture is mixed before freeze drying in proportion 1:1, and then freeze dried until moisture mass fraction is no more than 4%. Finally, it is packed into ampoules. The end product contains virus raw materials, peptone, sucrose, gelatine and demineralised water.

EFFECT: high-performance production of standard and innocuous rinderpest virus-vaccine for minor ruminants stable for storage conditions.

2 cl, 3 ex

FIELD: biochemistry.

SUBSTANCE: invention refers to antibodies that link with CTGF. Antibodies, in particular, are directed to the areas of CTFG participating in different types of biological activity related to fibrosis. The invention also refers to the method of antibodies application in pharmaceutical compositions for the treatment of CTGF-related diseases including localised and systemic fibrotic diseases such as diseases of lungs, liver, heart, skin and kidneys, for neutralisation of biological activity of CTGF and method of treatment and prophylaxis of CTGF-related diseases. The invention covers polynucleotide sequence and its variants coding the specified antibody as well as the host cell and cell line № PTA-6006 (ATCC) producing the specified antibody.

EFFECT: use of the invention provides new specific means - antibodies which effectively neutralise certain types of CTGF activity in pathology and provide specificity and pharmacokinetic profile suitable for a therapeutic agent.

82 cl, 33 dwg, 4 tbl, 12 ex

FIELD: bioengineering.

SUBSTANCE: versions of the molecule binding CD45RO and CD45RB, and the anti-CD45RO and anti-CD45RB antibody are invented. In one of versions, the said molecule contains at least one antigen-binding site and includes the subsequently located hypervariable sites CDR1, CDR2 and CDR3. The molecule represents the humanised or monoclonal antibody. CDR1 has the amino acid sequence NYIIH, CDR2 has the amino acid sequence YFNPYNHGTKYNEKFKG and CDR3 has the amino acid sequence SGPYAWFDT. The molecule can additionally contain the subsequently located hypervariable sites CDR1', CDR2' and CDR3'. CDR1' has the amino acid sequence RASQNIGTSIQ, CDR2' has the amino acid sequence SSSESIS and CDR3' has the amino acid sequence QQSNTWPFT. In another version, the molecule contains both heavy and light chains where the amino acid sequences contain the corresponding CDR. The versions of the corresponding coding polynucleotide are disclosed; expression vector and based on it expression system. The host cell is disclosed basing on the expression system. The application of the molecule in treatment of autoimmune diseases, graft rejection, psoriasis, intestine inflammatory disease and allergy is described. The pharmaceutical composition for the said application is disclosed.

EFFECT: enables immunosuppressant induction; inhibiting T-cell response and primary lymphocyte response in mixed lymphocyte culture (MLC); prolongs survival period in mice with severe combined immunodeficiency SCID.

20 cl, 5 dwg, 2 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: methods include peroral, transbuccal, sublingual, intranasal, intraocular, intragastric, intraduodenal, local, rectal or vaginal introduction within twenty four hours of the first therapeutically effective amount of E-2-methoxy-N-(3 {4 (3-3-4 (6-methyl-pyridine-3-iloxy)-phenylamino)-chinasolin-6-yl}-allyl)-acetamide (E composition), making 25-100 mg/kg, and the second therapeutically effective amount of E composition making 25-100 mg/kg.

EFFECT: improved therapeutic scheme of ovary adenocarcinoma owing to selection of specified small doses and conditions of E composition introduction.

2 cl, 6 dwg, 7 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: substance of invention includes application of ligand associated with carrier, where ligand is protein FasL, or Fas leukocyte receptor-directed antibody, to reduce leukocyte activity for extracorporal application. Besides, this invention provides method of leukocyte activity reduction my means of specified module.

EFFECT: damaging action of associated activated leukocytes is inhibited by inactivation module within minutes.

9 cl, 1 ex, 1 tbl, 1 dwg

FIELD: medicine; veterinary science.

SUBSTANCE: invention can be used for effective treatment and prevention of infectious diseases of domestic animals, mainly of acute respiratory viral infections and acute respiratory diseases. Medicinal agent used for treatment of infectious diseases of domestic animals including diseases of viral aetiology contains activated-potentiated forms of antibodies to interferon alpha, beta or gamma, specific for related taxonomic category of animals produced by multiple serial dilution and external action under homeopathic technology causing subminute dose of antibodies.

EFFECT: agent has improved efficiency.

4 cl, 5 ex

FIELD: medicine.

SUBSTANCE: described humanised and chimeric CD20 antibodies are designed for treatment of CD20-positive malignant and autoimmune diseases. Antibody is effective with respect to depletion of B-cells of mammals in vivo, contains in variable region of H-chain of CDR3- sequence from antibody to human CD20 and practically all remains of consensus frame region (FR) of human H-chain of subgroup 111. According to invention antibody is used in composition or product, binding CD20. Besides, antibody is used for apoptosis induction, treatment of CB20-positive cancer, autoimmune disease, and rheumatic arthritis. Invention contains nucleic acid (NA) coding antibody, expression vector containing specified NA, and host cell producing recombinant antibody, as well as method of specified antibody production. According to invention antibodies are characterised by minimum antigenicity or no antigenicity at all, that enables to use them for continuous treatment overcoming limits of existing therapeutic compositions application.

EFFECT: enables to use for continuous treatment.

83 cl, 32 dwg, 12 tbl, 16 ex

FIELD: medicine; pharmacy.

SUBSTANCE: invention refers to antibodies developing modulated binding with FcγR, and antibody contains at least one amino acid substitute in Fc-zone of original Fc-polypeptide, specifically of human origin. Mentioned modulation is expressed in affinity increase of mentioned antibody relative to FcγR. Various antibody versions are designed, for example those developing modulated effector function, those containing of aglyconized Fc-variant of original Fc-polypeptide and those characterized by improved binding affinity to ligand Fc in comparison to aglyconized form of original Fc-polypeptide. Obtained antibodies are used in pharmaceutical formulation containing modulated binding with FcγR, and method of mammal medical treatment of relevant abnormalities.

EFFECT: improvement of antibody affinity.

67 cl, 44 dwg, 66 tbl, 12 ex

FIELD: medicine; immunology.

SUBSTANCE: sorbent is offered to remove immunoglobulin from human blood plasma. This sorbent contains agarous matrix covalently combined with ligand. As a ligand at that it contains F(ab)2 fragments of specific affinely-purified polyclonal antibodies blocking human immunoglobulin G. Sorbent is actually biologically inert, biocompatible agarous matrix. Sorbent is characterized with higher sorptive capacity and safety of immunosorbents used practical purposes, specifically for therapeutic aphaeresis in comparison to well-known polyclonal bodies based sorbents.

EFFECT: considerable reduction of prospective immunological response of human body for foreign protein.

1 ex, 1 tbl

FIELD: medicine, oncology, endocrinology, pharmacy.

SUBSTANCE: invention relates to an agent used in prophylaxis or treatment of patients suffering from anorexia and containing antibody raised against protein relates to the human parathyroid hormone (PTHrP) as an active component. Agent can comprise antibody raised against human PTHrP wherein antibody can represent human, humanized or chimeric one and shows the low antigenicity. Using the proposed agent provides improving a patient state suffering from malignant tumor.

EFFECT: valuable medicinal properties of agent.

6 cl, 6 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating nervous-muscular diseases in mammals due to introducing therapeutically efficient amounts of inhibitor GDF-8 and corticosteroid for a person who has the risk of the development of nervous-muscular disorder or who suffers with nervous-muscular lesion - muscular dystrophy, atrophy, in particular, induced with corticosteroids, for the period of time being sufficient to maintain the desired levels of muscular functions. This provides synergistic result in improving different muscular functions.

EFFECT: higher efficiency.

28 cl, 3 dwg, 4 ex, 6 tbl

FIELD: genetic engineering, immunology, medicine.

SUBSTANCE: invention relates to new antibodies directed against antigenic complex CD3 and can be used in therapeutic aims. Antibody IgG elicits the affinity binding with respect to antigenic complex CD3 wherein heavy chain comprises skeleton of the human variable region in common with at least one CD3 taken among amino acid sequences SEQ ID NO 2, 4 and 6 and their corresponding conservatively modified variants. Light chain comprises skeleton of the rodent variable region in common with at least one CD3 taken among amino acid sequences SEQ ID NO 8, 10 and 12 and their corresponding conservatively modified variants. Antibody is prepared by culturing procaryotic or eucaryotic cell co-transformed with vector comprising recombinant nucleic acid that encodes antibody light chain and vector comprising recombinant nucleic acid that encodes antibody heavy chain. Antibody is administrated in the patient suffering with malignant tumor or needing in immunosuppression in the effective dose. Invention provides preparing chimeric antibodies against CD3 that are produced by expression systems of procaryotic and eucaryotic cells with the enhanced yield.

EFFECT: improved preparing methods, valuable medicinal properties of antibody.

33 cl, 5 dwg, 1 ex

Up!